Introduction to Stimuli-Responsive Systems

Controllable drug release at target sites represents an important challenge in precision medicine today. With rapid advances in chemistry, materials, and biology, researchers are designing novel systems for biomedicine. Specifically, modern cleavable linker design focuses on endogenous biochemical signals. These signals include specific enzymes, pH levels, and redox species. These natural triggers allow for highly specific drug activation at the tumor site.

Mechanisms of Cleavable Linker Design

Furthermore, enzyme-cleavable linkers utilize proteases like cathepsin B to release cytotoxic payloads efficiently. Consequently, pH-responsive systems exploit the acidic nature of the endolysosomal compartment. This strategy ensures that the drug remains inactive during systemic circulation. Therefore, patients experience fewer side effects compared to traditional chemotherapy methods. In addition, researchers are developing dual-responsive linkers to target heterogeneous tumor environments. However, manufacturing complexity and regulatory pathways remain significant challenges for these smart systems.

Applications in Modern Medicine

Moreover, these advanced linkers are currently revolutionizing antibody-drug conjugates (ADCs) and nanocarriers. By optimizing structure-activity relationships, scientists can overcome common issues like drug resistance. Future directions involve the use of artificial intelligence to predict cleavage kinetics more accurately. This progress will eventually lead to more personalized and effective therapeutic regimens for complex diseases.

Frequently Asked Questions

How do enzyme-cleavable linkers improve drug targeting?

These linkers respond to specific proteases overexpressed in tumors, ensuring the payload is only released within the target tissue, which reduces systemic toxicity.

What role does pH play in stimuli-responsive drug delivery?

Many delivery systems use linkers that remain stable at a neutral physiological pH but degrade rapidly in the acidic environment of tumor cells or lysosomes.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Li E et al. Endogenous stimuli-responsive intelligent drug delivery systems: recent advances in cleavable linker design. Chem Commun (Camb). 2026 Apr 23. doi: 10.1039/d6cc00388e. PMID: 42023486.

Lu Yang et al. Recent Advances in Peptide Linkers of Antibody-Drug Conjugates. J Med Chem. 2025 Sep 11;68(17):18099-18113. doi: 10.1021/acs.jmedchem.5c01500.

Shaoting Li et al. Recent Advances in Peptide Linkers for Antibody-Drug Conjugates. J Med Chem. 2025 Oct 9;68(19):19871-19892. doi: 10.1021/acs.jmedchem.5c01982.